Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-5,609
Closed -$213K 363
2023
Q2
$213K Sell
5,609
-246
-4% -$9.81K 0.02% 326
2023
Q1
$221K Sell
5,855
-713
-11% -$27.4K 0.02% 298
2022
Q4
$278K Buy
6,568
+461
+8% +$19K 0.02% 245
2022
Q3
$196K Buy
6,107
+39
+0.6% +$1.37K 0.02% 277
2022
Q2
$197K Sell
6,068
-1,448
-19% -$46.9K 0.02% 281
2022
Q1
$272K Buy
7,516
+1,311
+21% +$45K 0.02% 263
2021
Q4
$245K Sell
6,205
-125
-2% -$5.21K 0.02% 258
2021
Q3
$277K Buy
6,330
+666
+12% +$29.9K 0.03% 210
2021
Q2
$231K Buy
5,664
+1,089
+24% +$42K 0.02% 227
2021
Q1
$150K Buy
4,575
+1,578
+53% +$59.3K 0.02% 280
2020
Q4
$122K Buy
2,997
+1,484
+98% +$55.5K 0.02% 266
2020
Q3
$55K Buy
1,513
+1,251
+477% +$45.2K 0.01% 360
2020
Q2
$9K Buy
262
+223
+572% +$6.08K ﹤0.01% 640
2020
Q1
$1K Buy
+39
New +$869 ﹤0.01% 891

Other funds holding GMAB

Ellevest Inc's GMAB Position: Q3 2023 in Review

Ellevest Inc sold out of Genmab (GMAB) in Q3 2023, closing a stake of 5,609 shares — an estimated $213K sold.

Ellevest Inc first reported a position in GMAB in Q1 2020 and held it in 14 quarters. The position peaked at $278K in Q4 2022. 233 funds tracked by Wall St. Rank hold GMAB as of Q3 2023.

  • Ellevest Inc reported no remaining Genmab position as of Q3 2023 after selling out during the quarter.
  • Ellevest Inc sold 5,609 Genmab shares in Q3 2023, an estimated $213K.
  • Ellevest Inc first reported a position in Genmab in Q1 2020 and held it in 14 quarters.
  • Ellevest Inc's Genmab position peaked at $278K in Q4 2022.
  • 233 funds tracked by Wall St. Rank held Genmab as of Q3 2023.

Based on Ellevest Inc's 13F filing for Q3 2023, filed 9 Nov 2023.